|Bid||140.00 x 800|
|Ask||144.89 x 800|
|Day's Range||141.77 - 148.38|
|52 Week Range||101.07 - 179.65|
|Beta (3Y Monthly)||2.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||178.33|
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / There has been some bad news in the market recently causing some securities to sell off. This has made for some desirable buying opportunities for savvy ...
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...
If you're interested in profiting from the marijuana movement, you might want to consider owning a marijuana exchange-traded fund.
GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.
Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.
Stock futures: Hot IPO Stitch Fix earnings topped, but other metrics missed. Stitch Fix stock dived. Marijuana plays New Age Beverages, India Globalization and DavidsTea were volatile.
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S. subsidiary is Greenwich Biosciences, announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering. GW expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...
The biggest market cap or the most hype doesn't always translate to the greatest stock performance.
CORAL GABLES, FL / ACCESSWIRE / September 28, 2018 / It's no secret that marijuana stocks are capturing a lot of attention lately and because of this, it's no wonder why one of the few cannabis ETFs that track the industry, the ETFMG Alternative Harvest ETF (MJ), has jumped by more than 30% since March. Alcoholic-beverage maker Constellation Brands' $4 billion investment in Canadian marijuana company Canopy Growth was a big catalyst in recent weeks. This was followed up by a number of other companies like Molson Coors and even Coca-Cola eyeing the cannabis market.